title: Chemotherapy for acute non-lymphocytic leukemia with low-dose cytosine arabinoside (Ara-C).
abstract: We administered low-dose cytosine arabinoside (Ara-C) to 32 newly diagnosed acute non-lymphocytic leukemia (ANLL) patients, 10 mg/m2 twice a day for 14-21 days, by subcutaneous injection or continuous intravenous infusion. CFU-GM of bone marrow cells were performed before low-dose Ara-C in some patients. Patients ranged in age from 21 to 78 years old. Ten showed complete remission and 16 partial response. The pretreatment CFU-GM pattern did not reflect the response to low-dose Ara-C. The major hematological effect of the treatment was myelosuppression, and most patients required platelet transfusion and the administration of antibiotics. Our study suggested that low-dose Ara-C treatment benefits some ANLL patients.
authors.affiliation: Department of Internal Medicine, Kaosiung Medical College, Taiwan, R.O.C.
authors.forename: S F
authors.initials: SF
authors.lastname: Lin
authors.forename: H W
authors.initials: HW
authors.lastname: Liu
authors.forename: T P
authors.initials: TP
authors.lastname: Chen
mesh_terms: D000328:Adult; D000368:Aged; D003561:Cytarabine / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged
chemical_list: D003561:Cytarabine